Correlation Between Passage Bio and Cue Biopharma
Can any of the company-specific risk be diversified away by investing in both Passage Bio and Cue Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Passage Bio and Cue Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Passage Bio and Cue Biopharma, you can compare the effects of market volatilities on Passage Bio and Cue Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Passage Bio with a short position of Cue Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Passage Bio and Cue Biopharma.
Diversification Opportunities for Passage Bio and Cue Biopharma
-0.47 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Passage and Cue is -0.47. Overlapping area represents the amount of risk that can be diversified away by holding Passage Bio and Cue Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cue Biopharma and Passage Bio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Passage Bio are associated (or correlated) with Cue Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cue Biopharma has no effect on the direction of Passage Bio i.e., Passage Bio and Cue Biopharma go up and down completely randomly.
Pair Corralation between Passage Bio and Cue Biopharma
Given the investment horizon of 90 days Passage Bio is expected to generate 0.91 times more return on investment than Cue Biopharma. However, Passage Bio is 1.1 times less risky than Cue Biopharma. It trades about 0.03 of its potential returns per unit of risk. Cue Biopharma is currently generating about -0.01 per unit of risk. If you would invest 98.00 in Passage Bio on August 31, 2024 and sell it today you would earn a total of 15.00 from holding Passage Bio or generate 15.31% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 99.73% |
| Values | Daily Returns |
Passage Bio vs. Cue Biopharma
Performance |
| Timeline |
| Passage Bio |
| Cue Biopharma |
Passage Bio and Cue Biopharma Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Passage Bio and Cue Biopharma
The main advantage of trading using opposite Passage Bio and Cue Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Passage Bio position performs unexpectedly, Cue Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will offset losses from the drop in Cue Biopharma's long position.| Passage Bio vs. Cue Biopharma | Passage Bio vs. Eliem Therapeutics | Passage Bio vs. Inhibrx | Passage Bio vs. Molecular Partners AG |
| Cue Biopharma vs. Coya Therapeutics, Common | Cue Biopharma vs. Lantern Pharma | Cue Biopharma vs. Fennec Pharmaceuticals | Cue Biopharma vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Complementary Tools
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world |